Core Insights - The company, Stone Four Pharmaceutical Group, has obtained the production registration approval from the National Medical Products Administration of China for the sustained-release capsules of Trospium Chloride (4mg) [1] - This approval classifies the drug as a Class 4 chemical drug and is considered equivalent to passing the consistency evaluation, making the company the third domestic enterprise to receive such approval [1] - Trospium Chloride sustained-release capsules are primarily used for the treatment of overactive bladder syndrome [1]